Hemaceutical Strategy

NYBCe’s Hemaceutical™ Strategy aims to raise the standard for transfusion medicine by acquiring, licensing, or co-developing technologies that will yield pharmaceuticalized products for transfusion.

NYBC Ventures Hemaceutical™ Investment Initiative

In partnership with New York Blood Center, NYBC Ventures has launched a Hemaceutical™ strategic investment initiative. The objective is to invest in significant innovations that enhance transfusable blood products’ safety, characterization, preservation, and standardization to a higher grade.